EX-21.1 5 v304169_ex21-1.htm EXHIBIT 21.1

EXHIBIT 21.1

Subsidiaries of NeoStem, Inc.(1) |  | Jurisdiction of Incorporation/Organization
NeoStem Therapies, Inc. |  | Delaware
Stem Cell Technologies, Inc. |  | Florida
NeoStem (China), Inc. |  | People’s Republic of China
Qingdao Niao Bio-Technology Ltd.(2) |  | People’s Republic of China
Beijing Ruijiao Bio-Technology Ltd.(2) |  | People’s Republic of China
Tianjin Niou Bio-Technology Ltd.(2) |  | People’s Republic of China
CBH Acquisition LLC |  | Delaware
China Biopharmaceuticals Holdings, Inc.(3) |  | Delaware
Suzhou Erye Pharmaceuticals Company Ltd.(3) |  | People’s Republic of China
Progenitor Cell Therapy, LLC |  | Delaware
PCT Allendale, LLC(4) |  | New Jersey
NeoStem Family Storage, LLC(4) (5) |  | Delaware
Athelos Corporation(6) |  | Delaware
Amorcyte, LLC |  | Delaware
NeoStem Diagnostics, Inc. |  | Delaware

| (1) | Unless otherwise specified, each entity listed in the chart is a wholly-owned direct subsidiary of NeoStem, Inc.

| (2) | Because certain regulations in the People’s Republic of China (“PRC”) currently restrict or prohibit foreign entities from holding certain licenses and controlling certain businesses in China, the Company created a wholly foreign-owned entity, or WFOE, NeoStem (China), to implement its initiatives in China. To comply with China’s foreign investment regulations with respect to stem cell-related activities, these business initiatives in China are conducted via Chinese domestic entities that are controlled by the WFOE through various contractual arrangements and under the principles of consolidation the Company consolidates 100% of their operations.

| (3) | China Biopharmaceuticals Holdings, Inc. is a wholly-owned subsidiary of CBH Acquisition LLC and holds the 51% interest in Suzhou Erye Pharmaceutical Company Ltd. (“Erye”). Suzhou Erye Economy and Trading Co. Ltd. owns the remaining 49% interest in Erye.

| (4) | This entity is a wholly-owned subsidiary of Progenitor Cell Therapy, LLC.

| (5) | Formerly known as DomaniCell, LLC.

| (6) | Progenitor Cell Therapy, LLC holds approximately an 80% interest in this entity.